E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cytomegalovirus infection |
|
E.1.1.1 | Medical condition in easily understood language |
Cytomegalovirus infection |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy CMV-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to evaluate antigen-specific binding antibody (bAb) responses following vaccination with mRNA-1647 at different dose levels administered in a 3-dose schedule (0, 2, and 6 months) in participants 9 to 15 years of age, and to evaluate antigen-specific bAb responses following vaccination with mRNA-1647 at dose level C administered in participants 16 to 25 years of age. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Is a female or male 9 to 15 years of age or is a female 16 to 25 years of age at the time of consent. - Is in good general health, in the opinion of the Investigator, and is capable of complying with study procedures. - For the CMV-seronegative cohorts: At the Screening visit, is CMV immunoglobulin G (IgG)-negative and CMV immunoglobulin M (IgM)-negative. - For CMV-seropositive cohorts: At the Screening visit, is CMV IgG-positive and CMV IgM-negative, CMV IgG-positive and CMV IgM-positive, or CMV IgG-positive and CMV IgM-indeterminate. Participants with an isolated positive or indeterminate result for CMV IgM (that is, CMV IgG-negative and either CMV IgM-positive or CMV IgM-indeterminate) will not be eligible for enrollment but may be rescreened after at least 6 weeks from the initial CMV Screening. Participants with an indeterminate result for CMV IgG, regardless of IgM result, will not be eligible for enrollment but may be rescreened after at least 6 weeks from the initial CMV screening. - If 9 to 15 years of age, has a body mass index (BMI) at or above the third percentile according to World Health Organization (WHO) Child Growth Standards. If 16 to 25 years of age: has a BMI of 15 to 35 kilograms (kg)/square meter (m^2). - For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 3 months following vaccine administration. |
|
E.4 | Principal exclusion criteria |
- Has a history of a diagnosis or condition that, in the judgment of Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. Clinically unstable is defined as diagnosis or condition requiring significant changes in management or medication within the 2 months prior to Screening and includes ongoing workup of an undiagnosed illness that could lead to a new diagnosis or condition. - Has received, or plans to receive, any non-study vaccine < 28 days prior to or after any study injection. - Has a screening liver function test (aspartate aminotransferase, alanine aminotransferase, total bilirubin) or a screening creatinine result of Toxicity Grade ≥1. - Has a Screening hematology or coagulation result of Toxicity Grade ≥1. - Is acutely ill or febrile (body temperature ≥38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) at the Screening Visit. - Has received systemic immunosuppressants or immune-modifying drugs for > 14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥1 milligrams (mg)/kg/day or ≥10 mg/day prednisone equivalent). - Has received an antiviral with activity against CMV (ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir, acyclovir, valacyclovir) <2 weeks prior to the day of the first study injection (Day 1) or plans to do so during the course of the study. - Reports a history of myocarditis, pericarditis, or myopericarditis. - Has reported medical history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); or a positive screening test for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or HIV 1 or 2 antibodies. - Has previously received an investigational CMV vaccine. - Has received systemic immunoglobulins or blood products <3 months prior to the day of the first study injection (Day 1). - Has donated ≥ 450 milliliter (mL) of blood products <28 days prior to the day of the first study injection (Day 1). - Has participated in an interventional clinical study <28 days prior to the day of the first study injection (Day 1) or plans to do so while enrolled in the study. Note: Other inclusion and exclusion criteria may apply. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Number of Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) 2. Number of Unsolicited Adverse Events (AEs) 3. Number of Medically Attended Adverse Events (MAAEs) 4. Number of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and AEs Leading to Discontinuation 5. Geometric Mean Titer (GMT) of Anti-CMV Neutralizing Antibodies (nAbs) 6. Geometric Mean Fold-Rise (GMFR) of Anti-CMV nAbs 7. Number of Participants with ≥2-Fold, 3-Fold, and 4-Fold increases Over Baseline of Anti-CMV Antibodies |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. Up to Day 176 (7 days after each study injection) 2. Up to Day 197 (28 days after each study injection) 3. Up to Day 347 (6 months after the last study injection) 4 - 7. Up to Day 527 (end of study) |
|
E.5.2 | Secondary end point(s) |
1. Geometric Mean Concentration (GMC) of Binding Anti-Glycoprotein B (gB) Specific Immunoglobulin G (IgG) and Anti-Pentamer Specific IgG 2. Number of Participants with ≥2-Fold, 3-Fold, and 4-Fold Increases Over Baseline of Binding Anti-gB and Anti-pentamer Specific IgG 3. GMFR of Binding Anti-gB and Anti-pentamer Specific IgG |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1-3. Up to Day 527 (end of study) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Dose-ranging and safety expansion study. |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Sequential assignment. Part 1 is open-label. Part 2 of the study is randomized (observer-blinded). |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 5 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Canada |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end-of-study is defined as completion of the last visit (EoS; Day 527) of the last participant in the study or last scheduled procedure as shown in the schedule of assessments for the last participant in the study globally. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 9 |